Sodium-glucose cotransporter 2 (SGLT-2) inhibitors for patients with Type 2 diabetes

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Standard

Sodium-glucose cotransporter 2 (SGLT-2) inhibitors for patients with Type 2 diabetes. / Røder, Michael Einar; Storgaard, Heidi; Rungby, Jørgen; Knop, Filip Krag; Vilsbøll, Tina.

I: Ugeskrift for Laeger, Bind 178, Nr. 38, 19.09.2016.

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Harvard

Røder, ME, Storgaard, H, Rungby, J, Knop, FK & Vilsbøll, T 2016, 'Sodium-glucose cotransporter 2 (SGLT-2) inhibitors for patients with Type 2 diabetes', Ugeskrift for Laeger, bind 178, nr. 38.

APA

Røder, M. E., Storgaard, H., Rungby, J., Knop, F. K., & Vilsbøll, T. (2016). Sodium-glucose cotransporter 2 (SGLT-2) inhibitors for patients with Type 2 diabetes. Ugeskrift for Laeger, 178(38).

Vancouver

Røder ME, Storgaard H, Rungby J, Knop FK, Vilsbøll T. Sodium-glucose cotransporter 2 (SGLT-2) inhibitors for patients with Type 2 diabetes. Ugeskrift for Laeger. 2016 sep. 19;178(38).

Author

Røder, Michael Einar ; Storgaard, Heidi ; Rungby, Jørgen ; Knop, Filip Krag ; Vilsbøll, Tina. / Sodium-glucose cotransporter 2 (SGLT-2) inhibitors for patients with Type 2 diabetes. I: Ugeskrift for Laeger. 2016 ; Bind 178, Nr. 38.

Bibtex

@article{fc94805cd11c43d7b9c7507e9163cce2,
title = "Sodium-glucose cotransporter 2 (SGLT-2) inhibitors for patients with Type 2 diabetes",
abstract = "The sodium-glucose cotransporter 2 inhibitor (SGLT-2i)-class is efficacious as monotherapy and as add-on therapy with an expected lowering of the glycated haemoglobin (HbA1c) concentration of approximately 7 mmol/mol. Side effects relate to the mode of action, genital infections are the main problem. Extremely rare cases of ketoacidosis are reported, mostly in patients with Type 1 diabetes. One SGLT-2i, empagliflozin, has been shown to reduce cardiovascular mortality and progression of kidney disease in patients with Type 2 diabetes and cardiovascular disease. Outcome trials for other SGLT-2i are pending. SGLT-2i are now in guidelines as a possible second-line therapy or in case of metformin intolerance. ",
author = "R{\o}der, {Michael Einar} and Heidi Storgaard and J{\o}rgen Rungby and Knop, {Filip Krag} and Tina Vilsb{\o}ll",
year = "2016",
month = sep,
day = "19",
language = "English",
volume = "178",
journal = "Ugeskrift for Laeger",
issn = "0041-5782",
publisher = "Almindelige Danske Laegeforening",
number = "38",

}

RIS

TY - JOUR

T1 - Sodium-glucose cotransporter 2 (SGLT-2) inhibitors for patients with Type 2 diabetes

AU - Røder, Michael Einar

AU - Storgaard, Heidi

AU - Rungby, Jørgen

AU - Knop, Filip Krag

AU - Vilsbøll, Tina

PY - 2016/9/19

Y1 - 2016/9/19

N2 - The sodium-glucose cotransporter 2 inhibitor (SGLT-2i)-class is efficacious as monotherapy and as add-on therapy with an expected lowering of the glycated haemoglobin (HbA1c) concentration of approximately 7 mmol/mol. Side effects relate to the mode of action, genital infections are the main problem. Extremely rare cases of ketoacidosis are reported, mostly in patients with Type 1 diabetes. One SGLT-2i, empagliflozin, has been shown to reduce cardiovascular mortality and progression of kidney disease in patients with Type 2 diabetes and cardiovascular disease. Outcome trials for other SGLT-2i are pending. SGLT-2i are now in guidelines as a possible second-line therapy or in case of metformin intolerance.

AB - The sodium-glucose cotransporter 2 inhibitor (SGLT-2i)-class is efficacious as monotherapy and as add-on therapy with an expected lowering of the glycated haemoglobin (HbA1c) concentration of approximately 7 mmol/mol. Side effects relate to the mode of action, genital infections are the main problem. Extremely rare cases of ketoacidosis are reported, mostly in patients with Type 1 diabetes. One SGLT-2i, empagliflozin, has been shown to reduce cardiovascular mortality and progression of kidney disease in patients with Type 2 diabetes and cardiovascular disease. Outcome trials for other SGLT-2i are pending. SGLT-2i are now in guidelines as a possible second-line therapy or in case of metformin intolerance.

UR - http://www.scopus.com/inward/record.url?scp=85056381215&partnerID=8YFLogxK

M3 - Review

C2 - 27649712

AN - SCOPUS:85056381215

VL - 178

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

IS - 38

ER -

ID: 305723494